BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND JAK3, L-JAK, 3718, ENSG00000105639, P52333, JAKL, JAK-3, LJAK, JAK3_HUMAN
36 results:

  • 1. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
    De SK
    Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
    Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
    Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions.
    Dvorak CC; Haddad E; Heimall J; Dunn E; Cowan MJ; Pai SY; Kapoor N; Satter LF; Buckley RH; O'Reilly RJ; Chandra S; Bednarski JJ; Williams O; Rayes A; Moore TB; Ebens CL; Davila Saldana BJ; Petrovic A; Chellapandian D; Cuvelier GDE; Vander Lugt MT; Caywood EH; Chandrakasan S; Eissa H; Goldman FD; Shereck E; Aquino VM; Desantes KB; Madden LM; Miller HK; Yu L; Broglie L; Gillio A; Shah AJ; Knutsen AP; Andolina JP; Joshi AY; Szabolcs P; Kapadia M; Martinez CA; Parrot RE; Sullivan KE; Prockop SE; Abraham RS; Thakar MS; Leiding JW; Kohn DB; Pulsipher MA; Griffith LM; Notarangelo LD; Puck JM
    J Allergy Clin Immunol; 2023 Feb; 151(2):547-555.e5. PubMed ID: 36456360
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Suppressive function of bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-187 in prostate cancer.
    Li C; Sun Z; Song Y; Zhang Y
    Cancer Biol Ther; 2022 Dec; 23(1):1-14. PubMed ID: 36245088
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. IL-7: Comprehensive review.
    Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
    Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired jak3 mutations conferring IL-7 hypersensitivity.
    Das Gupta D; Paul C; Samel N; Bieringer M; Staudenraus D; Marini F; Raifer H; Menke L; Hansal L; Camara B; Roth E; Daum P; Wanzel M; Mernberger M; Nist A; Bauer UM; Helmprobst F; Buchholz M; Roth K; Bastian L; Hartmann AM; Baldus C; Ikuta K; Neubauer A; Burchert A; Jäck HM; Klein M; Bopp T; Stiewe T; Pagenstecher A; Lohoff M
    Cell Death Differ; 2022 Nov; 29(11):2163-2176. PubMed ID: 35459909
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Immune cells surveil aberrantly sialylated O-glycans on megakaryocytes to regulate platelet count.
    Lee-Sundlov MM; Burns RT; Kim TO; Grozovsky R; Giannini S; Rivadeneyra L; Zheng Y; Glabere SH; Kahr WHA; Abdi R; Despotovic JM; Wang D; Hoffmeister KM
    Blood; 2021 Dec; 138(23):2408-2424. PubMed ID: 34324649
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate.
    Zhu J; Yang T; Tang M; Yang Z; Pei H; Ye H; Tang Y; Cheng Z; Lin P; Chen L
    Biomed Pharmacother; 2021 May; 137():111373. PubMed ID: 33761599
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the bone Marrow Pathology Group.
    Weinberg OK; Chisholm KM; Ok CY; Fedoriw Y; Grzywacz B; Kurzer JH; Mason EF; Moser KA; Bhattacharya S; Xu M; Babu D; Foucar K; Tam W; Bagg A; Orazi A; George TI; Wang W; Wang SA; Arber DA; Hasserjian RP
    Mod Pathol; 2021 Jul; 34(7):1358-1366. PubMed ID: 33526873
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Curcumin Analogue L48H37 Suppresses Human Osteosarcoma U2OS and MG-63 Cells' Migration and Invasion in Culture by Inhibition of uPA via the JAK/STAT Signaling Pathway.
    Lu KH; Wu HH; Lin RC; Lin YC; Lu PW; Yang SF; Yang JS
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374783
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
    Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Differences in Mutational Profile between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma Identified Using Next Generation Sequencing.
    Borowczyk M; Szczepanek-Parulska E; Dębicki S; Budny B; Verburg FA; Filipowicz D; Więckowska B; Janicka-Jedyńska M; Gil L; Ziemnicka K; Ruchała M
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31248021
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.
    Sekiguchi N; Nomoto J; Nagata A; Kiyota M; Fukuda I; Yamada K; Takezako N; Kobayashi Y
    Biomed Res Int; 2018; 2018():6728128. PubMed ID: 30402490
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.
    Haddad E; Logan BR; Griffith LM; Buckley RH; Parrott RE; Prockop SE; Small TN; Chaisson J; Dvorak CC; Murnane M; Kapoor N; Abdel-Azim H; Hanson IC; Martinez C; Bleesing JJH; Chandra S; Smith AR; Cavanaugh ME; Jyonouchi S; Sullivan KE; Burroughs L; Skoda-Smith S; Haight AE; Tumlin AG; Quigg TC; Taylor C; Dávila Saldaña BJ; Keller MD; Seroogy CM; Desantes KB; Petrovic A; Leiding JW; Shyr DC; Decaluwe H; Teira P; Gillio AP; Knutsen AP; Moore TB; Kletzel M; Craddock JA; Aquino V; Davis JH; Yu LC; Cuvelier GDE; Bednarski JJ; Goldman FD; Kang EM; Shereck E; Porteus MH; Connelly JA; Fleisher TA; Malech HL; Shearer WT; Szabolcs P; Thakar MS; Vander Lugt MT; Heimall J; Yin Z; Pulsipher MA; Pai SY; Kohn DB; Puck JM; Cowan MJ; O'Reilly RJ; Notarangelo LD
    Blood; 2018 Oct; 132(17):1737-1749. PubMed ID: 30154114
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. B-cell differentiation and IL-21 response in
    Miggelbrink AM; Logan BR; Buckley RH; Parrott RE; Dvorak CC; Kapoor N; Abdel-Azim H; Prockop SE; Shyr D; Decaluwe H; Hanson IC; Gillio A; Dávila Saldaña BJ; Eibel H; Hopkins G; Walter JE; Whangbo JS; Kohn DB; Puck JM; Cowan MJ; Griffith LM; Haddad E; O'Reilly RJ; Notarangelo LD; Pai SY
    Blood; 2018 Jun; 131(26):2967-2977. PubMed ID: 29728406
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
    Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
    Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
    de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
    Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.
    Kurt H; Jorgensen JL; Amin HM; Patel KP; Wang SA; Lin P; Kanagal-Shamanna R; Loghavi S; Thakral B; Khogeer HA; Jabbour EJ; Li S; Yin CC; Medeiros LJ; Khoury JD
    Eur J Haematol; 2018 May; 100(5):444-454. PubMed ID: 29385279
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mutant jak3 signaling is increased by loss of wild-type jak3 or by acquisition of secondary jak3 mutations in T-ALL.
    Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
    Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.